Prokinetic · Laxative
A selective serotonin 5HT4-receptor agonist with prokinetic properties.
Increased plasma concentrations of prucalopride, potentially leading to an increased incidence or severity of prucalopride-related adverse effects (e.g., headache, nausea, diarrhea, abdominal pain).
Monitor for increased adverse effects of prucalopride. A dose reduction of prucalopride may be considered if adverse effects become bothersome or severe, especially in patients with renal impairment.
Source: DDInter
Increased plasma concentrations of prucalopride, potentially leading to an increased incidence or severity of prucalopride-related adverse effects (e.g., headache, nausea, diarrhea, abdominal pain).
Monitor for increased adverse effects of prucalopride. A dose reduction of prucalopride may be considered if adverse effects become bothersome or severe, especially in patients with renal impairment.
Increased plasma concentrations of prucalopride, potentially leading to an increased incidence or severity of prucalopride-related adverse effects (e.g., headache, nausea, diarrhea, abdominal pain).
Monitor for increased adverse effects of prucalopride. A dose reduction of prucalopride may be considered if adverse effects become bothersome or severe, especially in patients with renal impairment.
Source: DDInter
Increased plasma concentrations of prucalopride, potentially leading to an increased incidence or severity of prucalopride-related adverse effects (e.g., headache, nausea, diarrhea, abdominal pain).
Monitor for increased adverse effects of prucalopride. A dose reduction of prucalopride may be considered if adverse effects become bothersome or severe, especially in patients with renal impairment.
Increased plasma concentrations of prucalopride, potentially leading to an increased incidence or severity of prucalopride-related adverse effects (e.g., headache, nausea, diarrhea, abdominal pain).
Monitor for increased adverse effects of prucalopride. A dose reduction of prucalopride may be considered if adverse effects become bothersome or severe, especially in patients with renal impairment.
Source: DDInter
Increased plasma concentrations of prucalopride, potentially leading to an increased incidence or severity of prucalopride-related adverse effects (e.g., headache, nausea, diarrhea, abdominal pain).
Monitor for increased adverse effects of prucalopride. A dose reduction of prucalopride may be considered if adverse effects become bothersome or severe, especially in patients with renal impairment.
Source: DDInter
Increased plasma concentrations of prucalopride, potentially leading to an increased incidence or severity of prucalopride-related adverse effects (e.g., headache, nausea, diarrhea, abdominal pain).
Monitor for increased adverse effects of prucalopride. A dose reduction of prucalopride may be considered if adverse effects become bothersome or severe, especially in patients with renal impairment.
Source: DDInter
Increased plasma concentrations of prucalopride, potentially leading to an increased incidence or severity of prucalopride-related adverse effects (e.g., headache, nausea, diarrhea, abdominal pain).
Monitor for increased adverse effects of prucalopride. A dose reduction of prucalopride may be considered if adverse effects become bothersome or severe, especially in patients with renal impairment.
Source: DDInter
4 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team